Exelixis, Inc. (EXEL)
NASDAQ • Healthcare
Last close at November 18, 2026 at 21:00 UTC
Metrics Over Time
Where the Money Goes
Q4 2026In plain terms: out of every $100 in revenue, Exelixis, Inc. keeps $33 as net profit.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Feb 9
in 82 daysQ1 2027% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Exelixis beat expectations on both the top and bottom line in the third fiscal quarter of 2026, reported October 29, 2026, with adjusted EPS of $0.94 topping the $0.89 estimate (+6%) and revenue of $658.7 million topping the $646.5 million estimate (+1.9%). Revenue rose 10.2% to about $658.7 million from roughly $597.8 million a year ago, with the U.S. business contributing the majority as U.S. revenue increased 11.5% to about $609.1 million, while Europe revenue edged down 1.5% to roughly $44.3 million and Japan revenue fell 16.3% to about $5.3 million. Profitability tracked higher year over year as net income increased 12.7% to about $218.1 million, up from roughly $193.6 million a year earlier, alongside GAAP operating income of about $268.4 million. On the bottom line, adjusted EPS rose 20.5% from $0.78 a year ago. The quarter generated operating cash flow of about $280.0 million, and the company repurchased roughly $250.0 million of stock.
About Exelixis, Inc.
Exelixis, Inc. is a NASDAQ-listed biotechnology company that develops and commercializes cancer medicines and other therapies, generating $2.3 billion in FY2025 revenue. Its marketed portfolio centers on CABOMETYX tablets, COMETRIQ capsules, and COTELLIC for oncology, alongside MINNEBRO for hypertension, with commercial activity in the United States and Japan.
Today's Snapshot
EXEL closed slightly lower at 68.29, while its sector was weaker. Trading was lighter than usual, with volume about two-thirds of its usual level. Exelixis discussed zanza, an experimental cancer drug, and its seven pivotal trials at a healthcare conference.
Trading Volume
Below 10d avg (2.9M)
1.8M
vs S&P 500 Today
Inline with Market
-0.05%
Updated: November 18, 2026 at 21:24 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$54.06 - $68.88Buy
- RSI (14)55.01Neutral
- Stochastic %K (14, 3, 3)31.16Neutral
- MACD Level (12, 26)1.76Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.